Efficacy News and Research

RSS

Clinical results of FlexStent Femoropopliteal Self Expanding Stent System presented

Interim six month clinical results on the use of the FlexStent Femoropopliteal Self Expanding Stent System in the Superficial Femoral Artery were presented today at the VIVA conference by Dr. William Gray of NY Columbia-Presbyterian Hospital.

24 Oct 2009

Study reveals benefits of recombinant human C1 inhibitor in treating ischemic brain injury

Biotech company Pharming Group NV announced today publication of a preclinical study showing the benefit of using recombinant human C1 inhibitor (rhC1INH) in ischemic brain injury.

23 Oct 2009

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

Based on an extensive review of the highest quality scientific literature on psoriasis and the opinion of recognized psoriasis experts, the American Academy of Dermatology (Academy) has released new guidelines of care for the management and treatment of psoriasis with ultraviolet (UV) light therapy, also known as phototherapy. Recommendations for the use of the most common forms of UV light therapy, as stand-alone treatments or in conjunction with other therapies, were outlined, including patient considerations.

23 Oct 2009

New Category I CPT code for AspirinWorks Test Kit

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, announced today that a new Category I Current Procedural Terminology (CPT) code has been published by the American Medical Association (AMA) for the AspirinWorks Test Kit.

23 Oct 2009

AEOL 10150 increases regeneration of GI stem cells: NIAID study results

Aeolus Pharmaceuticals, Inc. announced today that recent experiments in preclinical models conducted by the National Institutes of Health’s (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasure Development program have shown that AEOL 10150 can effectively increase regeneration of gastro-intestinal (GI) stem cells, reduce the severity and duration of diarrhea and improve survival when administered at 24 hours after doses of total-body irradiation that produce the lethal GI syndrome.

23 Oct 2009

Japanese Ministry approves marketing of AMS800 Artificial Urinary Sphincter in Japan

American Medical Systems®, a leading provider of world-class devices and therapies for both male and female pelvic health, today announced that it has received clearance from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market and distribute its AMS 800 Artificial Urinary Sphincter (AUS) in Japan, effective September 7, 2009.

23 Oct 2009

Liraglutide drug causes less nausea and hypoglycaemia compared to exenatide

New data on patient treatment satisfaction from the LEAD(TM) 6 trial presented on the 22nd October at the 20th World Diabetes Congress (International Diabetes Federation) shows that patients have higher overall treatment satisfaction with liraglutide than they do with exenatide.

23 Oct 2009

Positive results from Phase 2 clinical trial of ARX-03 announced

AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical trial of ARX-03, a proprietary sublingual dosage form combining an opioid, sufentanil, with a benzodiazepine, triazolam.

23 Oct 2009

Positive results from Aerie Pharmaceuticals’ Phase 2a study of its Rho-kinase inhibitor

Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive results from a Phase 2a study of its Rho-kinase (ROCK) inhibitor, AR-12286. The study evaluated the safety, tolerability and efficacy of three different doses of AR-12286 in 88 patients with primary open angle glaucoma or ocular hypertension.

22 Oct 2009

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2009.

22 Oct 2009

Schering-Plough announces 2009 third quarter financial results

Schering-Plough Corporation (NYSE: SGP) today reported financial results for the 2009 third quarter.

22 Oct 2009

Pharmos announces results of its Phase 2b Dextofisopam trial

Pharmos Corporation (Pink Sheets: PARS); on September 14, 2009, Pharmos announced the results of its Phase 2b Dextofisopam trial for the treatment of diarrhea predominant and alternating diarrhea and constipation irritable bowel syndrome.

22 Oct 2009

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

Peregrine Pharmaceuticals, Inc. today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer.

22 Oct 2009

NicOx reports financial results for the first nine months of 2009

NicOx S.A. today reported financial results for the nine months ended September 30, 2009.

22 Oct 2009

HIV stigma: a barrier for proper care

The feeling of stigmatization that people living with HIV often experience doesn't only exact a psychological toll -new UCLA research suggests it can also lead to quantifiably negative health outcomes.

22 Oct 2009

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals, Inc. today announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes. ISIS 113715 is a novel insulin sensitizer that reduces the expression of protein tyrosine phosphatase-1B (PTP-1B). The study showed consistent and statistically significant reductions in multiple short and intermediate measures of glucose control.

22 Oct 2009

New diabetes algorithm released by AACE for the management of type 2 diabetes

A new, first-of-its-kind diabetes algorithm created to help achieve glycemic (blood sugar) control in type 2 patients was published online today in the September/October edition of Endocrine Practice.

22 Oct 2009

CombinatoRx announces Synavive Phase 2 extension trial results at the 2009 ACR meeting

CombinatoRx, Incorporated today announced the results of a 12 month knee osteoarthritis (OA) Phase 2 extension trial for Synavive™ (CRx-102) at the American College of Rheumatology (ACR) 2009 Annual Meeting in Philadelphia. The data demonstrated that Synavive-treated subjects maintained efficacy levels throughout the 12 month extension trial.

21 Oct 2009

Celsion completes patient enrollment in its global Phase III ThermoDox trial

Celsion Corporation announced today that it has completed a critical regulatory step in the countries of China and Japan to rapidly enroll patients in its global Phase III ThermoDox trial for the treatment of Hepatocellular Carcinoma (HCC), also known as primary liver cancer.

21 Oct 2009

Gamida Cell and Cellerixon collaborate to develop new line of cell therapeutics

Gamida Cell Ltd. and Cellerix, S.A. announced today that the companies are collaborating on a feasibility study to evaluate the added value of combining the proprietary technologies of each.

21 Oct 2009

Efficacy News and Research

Clinical results of FlexStent Femoropopliteal Self Expanding Stent System presented

Study reveals benefits of recombinant human C1 inhibitor in treating ischemic brain injury

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

New Category I CPT code for AspirinWorks Test Kit

AEOL 10150 increases regeneration of GI stem cells: NIAID study results

Japanese Ministry approves marketing of AMS800 Artificial Urinary Sphincter in Japan

Liraglutide drug causes less nausea and hypoglycaemia compared to exenatide

Positive results from Phase 2 clinical trial of ARX-03 announced

Positive results from Aerie Pharmaceuticals’ Phase 2a study of its Rho-kinase inhibitor

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Schering-Plough announces 2009 third quarter financial results

Pharmos announces results of its Phase 2b Dextofisopam trial

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

NicOx reports financial results for the first nine months of 2009

HIV stigma: a barrier for proper care

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

New diabetes algorithm released by AACE for the management of type 2 diabetes

CombinatoRx announces Synavive Phase 2 extension trial results at the 2009 ACR meeting

Celsion completes patient enrollment in its global Phase III ThermoDox trial

Gamida Cell and Cellerixon collaborate to develop new line of cell therapeutics

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News